×
0.0142421159715158 0.0142421159715158 0.0254832146490336 0.0183112919633774 0.00712105798575791 0.00610376398779252 -0.00153611393692781 -0.00315361139369266
Stockreport

Gemphire Announces Initiation of Phase 2a Clinical Trial of Gemcabene in Pediatric Non-Alcoholic Fatty Liver Disease (NAFLD)

GEMPHIRE THERAPEUTICS INC COMMON (GEMP)  More Company Research Source: GlobeNewswire
Last gemphire therapeutics inc common earnings: 8/13 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.gemphire.com
PDF Pediatric NAFLD/NASH is a large and untreated market; provides an opportunity to advance gemcabene in an underserved area with millions of affected patients Proof-of-concept clinical trial expands company’s differentiated NAFLD/NASH program across both adults and adolescents US Patent No. US 9,849,104, “Treatment of NASH with Gemcabene” issued, further enhancing intellectual property protection Company to host conference call and live webcast at 4:30 pm ET today LIVONIA, Mich., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and Nonalcoholic Steatohepatitis (NASH), announced today initiation of a Phase 2a proof-of-concept (POC) clinical trial investigating gemcabene as a treatment for pediatric nonalcoholic fatty liver disease (NAFLD).  NAFLD describes a continuum of disease from its mildest form of isola [Read more]

IMPACT SNAPSHOT EVENT TIME: GEMP
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS